Drug Profile
Valecobulin - Chong Kun Dang
Alternative Names: CKD-516; NOV 1204; NOV-120401Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antineoplastics; Benzophenones; Small molecules; Thiazoles; Triazoles
- Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Injection)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (PO)
- 13 Apr 2021 Chong Kun Dang Pharmaceutical completes a phase I/II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in South Korea (PO) (NCT03076957)